ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:4AB - US00287Y1091 - Common Stock
193.4 EUR
0 (0%)
Overall 4AB gets a fundamental rating of 5 out of 10. We evaluated 4AB against 82 industry peers in the Biotechnology industry. 4AB has a medium profitability rating, but doesn't score so well on its financial health evaluation. 4AB is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 4AB was profitable.
4AB had a positive operating cash flow in the past year.
Each year in the past 5 years 4AB has been profitable.
In the past 5 years 4AB always reported a positive cash flow from operatings.
1.2 Ratios
4AB's Return On Assets of 1.75% is fine compared to the rest of the industry. 4AB outperforms 71.95% of its industry peers.
Looking at the Return On Invested Capital, with a value of 15.64%, 4AB belongs to the top of the industry, outperforming 90.24% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for 4AB is in line with the industry average of 12.14%.
The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(15.64%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROIC | 15.64% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
4AB has a Profit Margin of 3.94%. This is in the better half of the industry: 4AB outperforms 75.61% of its industry peers.
4AB's Profit Margin has declined in the last couple of years.
4AB's Operating Margin of 33.05% is amongst the best of the industry. 4AB outperforms 87.80% of its industry peers.
4AB's Operating Margin has declined in the last couple of years.
4AB has a better Gross Margin (71.16%) than 60.98% of its industry peers.
In the last couple of years the Gross Margin of 4AB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 4AB is creating value.
4AB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, 4AB has more shares outstanding
Compared to 1 year ago, 4AB has a worse debt to assets ratio.
2.2 Solvency
4AB has an Altman-Z score of 2.45. This is not the best score and indicates that 4AB is in the grey zone with still only limited risk for bankruptcy at the moment.
4AB has a better Altman-Z score (2.45) than 68.29% of its industry peers.
The Debt to FCF ratio of 4AB is 3.49, which is a good value as it means it would take 4AB, 3.49 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 3.49, 4AB is doing good in the industry, outperforming 76.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Altman-Z | 2.45 |
ROIC/WACC1.88
WACC8.32%
2.3 Liquidity
A Current Ratio of 0.72 indicates that 4AB may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.72, 4AB is doing worse than 79.27% of the companies in the same industry.
4AB has a Quick Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
4AB's Quick ratio of 0.60 is on the low side compared to the rest of the industry. 4AB is outperformed by 80.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
4AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.09%.
The Earnings Per Share has been growing slightly by 2.51% on average over the past years.
Looking at the last year, 4AB shows a small growth in Revenue. The Revenue has grown by 7.40% in the last year.
4AB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.11% yearly.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
The Earnings Per Share is expected to grow by 13.69% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.42% on average over the next years.
EPS Next Y7.28%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
EPS Next 5Y13.69%
Revenue Next Year8.73%
Revenue Next 2Y9.07%
Revenue Next 3Y8.57%
Revenue Next 5Y7.42%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 24.02, 4AB is valued on the expensive side.
4AB's Price/Earnings ratio is a bit cheaper when compared to the industry. 4AB is cheaper than 78.05% of the companies in the same industry.
4AB's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.61.
The Price/Forward Earnings ratio is 15.64, which indicates a correct valuation of 4AB.
Based on the Price/Forward Earnings ratio, 4AB is valued cheaply inside the industry as 90.24% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of 4AB to the average of the S&P500 Index (24.01), we can say 4AB is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.02 | ||
| Fwd PE | 15.64 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 4AB is valued a bit cheaper than 74.39% of the companies in the same industry.
84.15% of the companies in the same industry are more expensive than 4AB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.4 | ||
| EV/EBITDA | 16.47 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of 4AB may justify a higher PE ratio.
A more expensive valuation may be justified as 4AB's earnings are expected to grow with 16.75% in the coming years.
PEG (NY)3.3
PEG (5Y)9.57
EPS Next 2Y19.81%
EPS Next 3Y16.75%
5. Dividend
5.1 Amount
4AB has a Yearly Dividend Yield of 3.09%. Purely for dividend investing, there may be better candidates out there.
4AB's Dividend Yield is rather good when compared to the industry average which is at 0.80. 4AB pays more dividend than 96.34% of the companies in the same industry.
4AB's Dividend Yield is rather good when compared to the S&P500 average which is at 1.87.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.09% |
5.2 History
On average, the dividend of 4AB grows each year by 7.72%, which is quite nice.
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
4AB pays out 489.69% of its income as dividend. This is not a sustainable payout ratio.
The dividend of 4AB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP489.69%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
FRA:4AB (12/22/2025, 7:00:00 PM)
193.4
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.96%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap341.81B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts77.89
Price Target213.25 (10.26%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.09% |
Yearly Dividend5.33
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)1.8%
PT rev (3m)12.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.79%
EPS NY rev (1m)0.91%
EPS NY rev (3m)-11.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.52%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.02 | ||
| Fwd PE | 15.64 | ||
| P/S | 6.73 | ||
| P/FCF | 20.4 | ||
| P/OCF | 19.25 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.47 |
EPS(TTM)8.05
EY4.16%
EPS(NY)12.37
Fwd EY6.4%
FCF(TTM)9.48
FCFY4.9%
OCF(TTM)10.05
OCFY5.2%
SpS28.73
BVpS-1.27
TBVpS-44.6
PEG (NY)3.3
PEG (5Y)9.57
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROCE | 20.86% | ||
| ROIC | 15.64% | ||
| ROICexc | 16.59% | ||
| ROICexgc | 572.43% | ||
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% | ||
| FCFM | 33% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 14.25% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 838.33% | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 2.45 |
F-Score7
WACC8.32%
ROIC/WACC1.88
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.28%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
EPS Next 5Y13.69%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.73%
Revenue Next 2Y9.07%
Revenue Next 3Y8.57%
Revenue Next 5Y7.42%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.29%
EBIT Next 3Y15.46%
EBIT Next 5Y11.36%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a valuation rating of 5 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ABBVIE INC (4AB.DE) stock?
The Price/Earnings (PE) ratio for ABBVIE INC (4AB.DE) is 24.02 and the Price/Book (PB) ratio is -151.95.
Can you provide the expected EPS growth for 4AB stock?
The Earnings per Share (EPS) of ABBVIE INC (4AB.DE) is expected to grow by 7.28% in the next year.